Stocktoria
Xenetic Biosciences, Inc. XBIO
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2016-11-07
Xenetic Biosciences, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -95.2% | -168.2% | -177.8% | -393.6% | -495.1% |
| Net margin | -90.1% | -158.4% | -162.8% | -383.9% | -486.4% |
| Return on assets | -32.1% | -57.4% | -39.0% | -44.5% | -28.5% |
| Return on equity | -36.2% | -65.9% | -42.2% | -48.0% | -30.7% |
| Current ratio | 8.32 | 7.37 | 11.84 | 12.72 | 13.18 |
| Revenue growth | 19.0% | -1.6% | 48.8% | 47.1% | 165.6% |
Source: SEC EDGAR filings · CIK 0001534525 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.